Abstract
Lysine (K)-specific demethylase 1A (LSD1/KDM1A) has been identified as a potential therapeutic target in solid cancers and more recently in acute myeloid leukemia. However, the potential side effects of a LSD1-inhibitory therapy remain elusive. Here, we show, with a newly established conditional in vivo knockdown model, that LSD1 represents a central regulator of hematopoietic stem and progenitor cells. LSD1 knockdown (LSD1-kd) expanded progenitor numbers by enhancing their proliferative behavior. LSD1-kd led to an extensive expansion of granulomonocytic, erythroid and megakaryocytic progenitors. In contrast, terminal granulopoiesis, erythropoiesis and platelet production were severely inhibited. The only exception was monopoiesis, which was promoted by LSD1 deficiency. Importantly, we showed that peripheral blood granulocytopenia, monocytosis, anemia and thrombocytopenia were reversible after LSD1-kd termination. Extramedullary splenic hematopoiesis contributed to the phenotypic reversion, and progenitor populations remained expanded. LSD1-kd was associated with the upregulation of key hematopoietic genes, including Gfi1b, Hoxa9 and Meis1, which are known regulators of the HSC/progenitor compartment. We also demonstrated that LSD1-kd abrogated Gfi1b-negative autoregulation by crossing LSD1-kd with Gfi1b:GFP mice. Taken together, our findings distinguish LSD1 as a critical regulator of hematopoiesis and point to severe, but reversible, side effects of a LSD1-targeted therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rice KL, Hormaeche I, Licht JD . Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26: 6697–6714.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941–953.
Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007; 446: 882–887.
Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 2012; 482: 221–225.
Adamo A, Sese B, Boue S, Castano J, Paramonov I, Barrero MJ et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol 2011; 13: 652–659.
Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436–439.
Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007; 9: 347–353.
Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009; 4: 80–93.
Weishaupt H, Sigvardsson M, Attema JL . Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells. Blood 2010; 115: 247–256.
Orford K, Kharchenko P, Lai W, Dao MC, Worhunsky DJ, Ferro A et al. Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Dev Cell 2008; 14: 798–809.
Saleque S, Kim J, Rooke HM, Orkin SH . Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 2007; 27: 562–572.
Hu X, Li X, Valverde K, Fu X, Noguchi C, Qiu Y et al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc Natl Acad Sci USA 2009; 106: 10141–10146.
Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009; 69: 2065–2071.
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341–11347.
Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512–520.
Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S et al. Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol 2011; 42: 1667–1675.
Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18: 605–611.
Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21: 473–487.
He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature 2010; 467: 95–98.
Acehan D, Vaz F, Houtkooper RH, James J, Moore V, Tokunaga C et al. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. J Biol Chem 2011; 286: 899–908.
Seibler J, Kleinridders A, Kuter-Luks B, Niehaves S, Bruning JC, Schwenk F . Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res 2007; 35: e54.
Vassen L, Okayama T, Moroy T . Gfi1b:green fluorescent protein knock-in mice reveal a dynamic expression pattern of Gfi1b during hematopoiesis that is largely complementary to Gfi1. Blood 2007; 109: 2356–2364.
Soriano P . Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70–71.
Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008; 135: 1118–1129.
Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004; 18: 2747–2763.
Nygren JM, Bryder D, Jacobsen SE . Prolonged cell cycle transit is a defining and developmentally conserved hemopoietic stem cell property. J Immunol 2006; 177: 201–208.
Saleque S, Cameron S, Orkin SH . The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev 2002; 16: 301–306.
Horman SR, Velu CS, Chaubey A, Bourdeau T, Zhu J, Paul WE et al. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood 2009; 113: 5466–5475.
Sugiyama T, Kohara H, Noda M, Nagasawa T . Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977–988.
Pronk CJ, Rossi DJ, Mansson R, Attema JL, Norddahl GL, Chan CK et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 2007; 1: 428–442.
Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9: 676–683.
Hall MA, Curtis DJ, Metcalf D, Elefanty AG, Sourris K, Robb L et al. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci USA 2003; 100: 992–997.
Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M . Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 2006; 108: 123–133.
Chen K, Liu J, Heck S, Chasis JA, An X, Mohandas N . Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA 2009; 106: 17413–17418.
Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF . Ineffective erythropoiesis in Stat5a(−/−)5b(−/−) mice due to decreased survival of early erythroblasts. Blood 2001; 98: 3261–3273.
Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM . Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One 2010; 5: e8581.
Hall MA, Slater NJ, Begley CG, Salmon JM, Van Stekelenburg LJ, McCormack MP et al. Functional but abnormal adult erythropoiesis in the absence of the stem cell leukemia gene. Mol Cell Biol 2005; 25: 6355–6362.
Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127: 4949–4958.
Kuter DJ, Rosenberg RD . The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720–2730.
Khandanpour C, Sharif-Askari E, Vassen L, Gaudreau MC, Zhu J, Paul WE et al. Evidence that growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells. Blood 2010; 116: 5149–5161.
Laurent B, Randrianarison-Huetz V, Kadri Z, Romeo PH, Porteu F, Dumenil D . Gfi-1B promoter remains associated with active chromatin marks throughout erythroid differentiation of human primary progenitor cells. Stem Cells 2009; 27: 2153–2162.
Metzger E, Muller JM, Ferrari S, Buettner R, Schule R . A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 2003; 22: 270–280.
van der Meer LT, Jansen JH, van der Reijden BA . Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia 2010; 24: 1834–1843.
Osawa M, Yamaguchi T, Nakamura Y, Kaneko S, Onodera M, Sawada K et al. Erythroid expansion mediated by the Gfi-1B zinc finger protein: role in normal hematopoiesis. Blood 2002; 100: 2769–2777.
Acknowledgements
We thank Tarik Möröy for the permission to use Gfi1b:GFP mice, Doris Schünke for excellent technical assistance performing electron microscopy, the WTZ hemato-oncology laboratory for technical support staining blood smears and cytospin preparations, and the WTZ Research Support Service (supported in part by the Deutsche Krebshilfe Comprehensive Cancer Center financing) for editing the manuscript. This work was supported by a grant to JHS from the Deutsche Krebshilfe (Nr. 108941), and grant support from the Stem Cell Network North-Rhine Westphalia to JRG.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Sprüssel, A., Schulte, J., Weber, S. et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 26, 2039–2051 (2012). https://doi.org/10.1038/leu.2012.157
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.157
Keywords
This article is cited by
-
New Treatments for Myelofibrosis
Current Treatment Options in Oncology (2023)
-
Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies
Leukemia (2022)
-
Decoding Human Hematopoietic Stem Cell Self-Renewal
Current Stem Cell Reports (2022)
-
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
Current Hematologic Malignancy Reports (2022)
-
Novel treatments for myelofibrosis: beyond JAK inhibitors
International Journal of Hematology (2022)